GEMCITABINE AND CAPECITABINE IN UNRESECTABLE OR METASTATIC CHOLANGIOCARCINOMA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out what effect (good and bad) the combination of the drugs capecitabine and gemcitabine will have on your tumor. This research is being done because right now there is no curative treatment for this type of cancer. Standard chemotherapy causes the tumor to shrink in 10%-15% of people with unresectable gallbladder or cholangiocarcinoma, but those responses last only 3-6 months. Better therapies are needed to treat patients with this disease. The patient will be asked for permission to submit their tissue samples and blood samples to that they may be studied. Scientist will study their tissue to see if they can predict survival by testing certain aspects of their tumor tissue. If they agree, tumor tissue that is left from the biopsy they have before they register to this study will be used for these tests. The blood sample will be taken before they start treatment. A consent form for use of specimens for research has information about using their tissue for research and asks if they will agree to allow us to keep some of the tissue that is left and use it for future studies.